EpiCypher introduces cloud-based epigenomic analysis platform
EpiCypher has launched CUTANA Cloud, a bioinformatics platform designed to streamline the analysis of chromatin mapping assays including CUT&RUN, CUT&Tag, and future applications such as ATAC-seq. Built on the DNAnexus precision health platform, the system aims to reduce the time required for researchers to process epigenomic data from weeks to hours.
Addressing bioinformatics workflow bottlenecks
The new platform addresses a common challenge in epigenomic research: lengthy waiting times for bioinformatics support. By providing user-friendly workflows, CUTANA Cloud enables wet-lab researchers to conduct secondary analysis and assess experimental outcomes independently. “EpiCypher is proud to offer CUTANA Cloud to chromatin and genomic researchers,” said Keith Maier, associate director of product development at EpiCypher. “With its intuitive, cloud-
based chromatin profiling analysis workflows, wet-lab researchers can rapidly complete secondary analysis and assess experimental success without waiting weeks to months for bioinformatic support.”
Cloud infrastructure and security features
The platform utilises DNAnexus infrastructure, which currently supports more than 60,000 registered users across 48 countries and manages over 125 petabytes of clinical, genomic, proteomic, and multiomic datasets. The system incorporates enterprise-grade security protocols and meets industry standards for precision health data quality, security, privacy, and regulatory compliance.
Epigenomic research examines the chemical and structural modifications that influence chromatin organisation, including histone modifications and transcription factor binding sites. These investigations provide insights into gene regulation mechanisms relevant to drug target identification, biomarker development, and treatment strategy design.
Kristy Cloyd-Warwick, SVP, customer experience at DNAnexus commented: “Our collaboration with EpiCypher exemplifies the DNAnexus commitment to working closely with our partners to pioneer new innovations and transform life sciences.
“Together, we’re empowering researchers to explore the epigenetic mechanisms that control gene regulation, and to turn those discoveries into better treatments and improved patient outcomes.”
As well as chromatin mapping technologies, EpiCypher also produces designer nucleosomes and complementary high-throughput assays.
For more information, visit: https://www.epicypher.com
Digital issue: Please click here for more information
